WithdrawnPHASE1, PHASE2NCT01460602

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

Studying MALT lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Louisiana State University Health Sciences Center Shreveport
Principal Investigator
Francesco Turturro, MD
LSUHSC-S
Intervention
MTD of Velcade, Nipent and Rituxan established in Part 1(drug)
Eligibility
18-85 years · All sexes
Timeline
2010 – 2014

Study locations (1)

Collaborators

Millennium Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01460602 on ClinicalTrials.gov

Other trials for MALT lymphoma

Additional recruiting or active studies for the same condition.

See all trials for MALT lymphoma →

← Back to all trials